Over the last 20 years, NovAliX has routinely used native MS. Our extensive track record of complex studies includes proteins, biologics, nucleic acids, lipids and sugars.
This fast and reliable technique can provide both qualitative and quantitative information.
All these data provide key elements to understand drug interaction modes. The NovAliX MS platform is also designed to support screening, including fragment libraries.
Find more information in the chapter on mass spectroscopy in the following book from Jean Paul Renaud (cofounder and President & Chief Scientific Officer at Urania Therapeutics also cofounder of NovAliX):